Greg Alton

If You Cure It, Will They Pay? Placing a Value on Lives

Mary Dwight, Reed Tuckson, Dean Rosen, Greg Alton

A healthcare sector conference examined the critical clash between high-cost breakthrough therapies like Kalydeco and Sovaldi and a reimbursement system ill-equipped to manage upfront expenses for long-term savings. Industry leaders, including representatives from Gilead Sciences and payer organizations, discussed a decisive shift toward value-based models where commercial viability now depends on real-world data proving total cost of care reduction. The event highlighted emerging trends in collaborative guidelines and investment strategies that prioritize cost-effective innovation and shared risk structures to prevent system-wide financial attrition.